QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 keybanc-initiates-coverage-on-avient-with-overweight-rating-announces-price-target-of-48

Keybanc analyst Aleksey Yefremov initiates coverage on Avient (NYSE:AVNT) with a Overweight rating and announces Price Targe...

 baird-maintains-neutral-on-avient-lowers-price-target-to-37

Baird analyst Ben Kallo maintains Avient (NYSE:AVNT) with a Neutral and lowers the price target from $43 to $37.

 avient-sees-q3-adj-eps-070-vs-068-est

Avient (NYSE:AVNT) is looking for Q3 Adj EPS of $0.70 vs $0.68 analyst estimate..

 avient-narrows-fy2025-adj-eps-guidance-from-270-294-to-277-287-vs-278-est

Avient (NYSE:AVNT) narrows FY2025 Adj EPS guidance from $2.70-$2.94 to $2.77-$2.87 vs $2.78 analyst estimate..

 avient-q2-adj-eps-080-beats-079-estimate-sales-866500m-beat-853250m-estimate

Avient (NYSE:AVNT) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.79 by 1.91 pe...

 germany-has-become-the-worlds-largest-cannabis-importer-here-are-the-stocks-benefiting

Germany became the world's top importer of medical cannabis, but political pressure could challenge telehealth-driven growth.

 morgan-stanley-maintains-equal-weight-on-avient-lowers-price-target-to-41

Morgan Stanley analyst Angel Castillo maintains Avient (NYSE:AVNT) with a Equal-Weight and lowers the price target from $51 ...

 wells-fargo-maintains-overweight-on-avient-raises-price-target-to-42

Wells Fargo analyst Michael Sison maintains Avient (NYSE:AVNT) with a Overweight and raises the price target from $39 to $42.

 avient-sees-q2-adj-eps-079-vs-079-est

Avient (NYSE:AVNT) is looking for Q2 Adj EPS of $0.79 vs $0.79 analyst estimate..

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION